Chief Operating Officer
Mary is an accomplished, senior biopharma executive with extensive experience across all aspects of global drug development and operational management. She joined ONK Therapeutics as COO in January 2021.
With an industry career spanning over 30 years, Mary was previously a consultant COO of BioInvent International, a public company focused on clinical development of antibody drugs for immunotherapy against cancer and Neuramedy, a South Korean company developing drugs for neurodegenerative diseases.
Prior to these roles, Mary was COO of Opsona Therapeutics a biotech company focused on the development of an antibody targeting TLR2 in several disease areas. Earlier in her career she held senior leadership roles at Elan Pharmaceuticals and Taro Pharmaceuticals.
She is eligible to act as a Qualified Person under EU clinical directive 2001/20/EC (Clinical Trials-Regulation EU No 536/2014) for the certification of medicinal products.
Mary has a first-class Masters in Pharmaceutical Science from the Royal College of Surgeons in Ireland.
She also has a Master’s degree in leadership from the Irish Management Institute and a Diploma in Company Direction and governance from the Institute of Directors.